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Abstract. The amyloid-β protein precursor (AβPP) is an integral membrane protein subjected to constitutive and regulated
proteolytic processing. We have previously demonstrated that protein kinase C ε (PKCε) plays a key role in the regulation
of AβPP metabolism via cholinergic receptors. The purpose of the present work is to clarify whether other putative signaling
systems are involved in the same pharmacological pathway. We focused particularly on casein kinase 2 (CK2), demonstrating
a direct interaction between PKCε and CK2 following cholinergic stimulation. Treatment of human neuroblastoma SH-SY5Y
cells with a selective inhibitor of CK2 reduced the effect of carbachol on the release of sAβPPα. This treatment did not influence
the activation and translocation of PKCε suggesting that the latter is located upstream of CK2. On the basis of our results, we
add another player to the complex cellular mechanisms regulating non-amyloidogenic processing of AβPP.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by depo-
sition in the brain of fibrillar aggregates of a peptide
named amyloid-β (Aβ), derived from proteolytic pro-
cessing of a larger precursor called the amyloid-β pro-
tein precursor (AβPP) [1].
AβPP is an integral membrane protein with a com-
plex proteolytic metabolism that can be simplified in
a so called “non amyloidogenic” pathway, based on
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the action of α-secretases cleaving AβPP inside the
Aβ region producing a soluble fragment sAβPPα, thus
precluding Aβ production, and in the “amyloidogenic”
pathway, based on the activities known as β- and γ-
secretase, which generates Aβ [2].
The most studied proteases involved in α-AβPP pro-
cessing are TNFα converting enzyme (TACE; ADAM-
17) [3] and ADAM10 [4,5]. Interestingly, while TACE
seems to be involved in the phorbol esters-mediated re-
lease of sAβPPα, ADAM10 has been shown to be in-
volved in both the regulated and constitutive secretion
of AβPP [6].
AβPP processing by α-secretase occurs via a con-
stitutive pathway and by receptor mediated activation
of multiple signal transduction pathways among which
protein kinase C (PKC) is a major player [7,8]. Among
others, cholinergic receptors (mAChR) conduce to an
increase in the release of soluble N-terminal AβPP
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derivates [9], and this has been the basis of numerous
studies that demonstrated that acetylcholinesterase in-
hibitors may influence the non amyloidogenic process-
ing of AβPP [10–12].
We have previously demonstrated that PKCε, among
other kinase isoforms, is specifically involved in
cholinergic-mediated AβPP processing [13], howev-
er, the exact target of PKC phosphorylation relat-
ed to AβPP processing is still elusive. Several ob-
servations in the literature suggest that activation of
AβPP cleavage/release by PKC involves phosphoryla-
tion/interaction with some still unknown components
of the processing pathway.
We turned our attention to casein kinase 2 (CK2),
an ubiquitous and essential serine/threonine protein ki-
nase, found in eukaryotic cells, with a list of more than
300 known protein substrates [14]. It has traditionally
been classified as a stable tetrameric complex consist-
ing of two catalytic subunits, α or α’, and two regula-
tory subunits β. The actual occurrence of the three pre-
dicted tetramers, α2β2, αα’β2, and α’2β2, has been
well documented [15]. Interestingly, some reports have
suggested that CK2 could be activated by PKC [16–
18]. Consequently, we inquired the possibility of a
CK2 participation in the sAβPPα release downstream
of cholinergic stimulation.
MATERIALS AND METHODS
Materials and chemicals
All culture media, supplements, and fetal calf serum
(FCS) were obtained from Euroclone (Life Science Di-
vision, Milan, Italy). Electrophoresis reagents were ob-
tained from Bio-Rad (Hercules, CA, USA), PULSinTM
was purchased from Polyplus-transfection SA (Ilkirch,
France) and the inhibitor peptide of PKCε transloca-
tion was purchased from Calbiochem (EMD Chemical
Inc., San Diego, CA, USA). All other reagents were
purchased from Sigma Chemical Co. (St. Louis, MO,
USA). Carbachol was dissolved in PBS and then dilut-
ed in serum free medium to working concentrations at
the time of use; inhibitor peptide (IP) of PKCε translo-
cation was dissolved in PBS and stored at −20◦C and
4,5,6,7-tetrabromobenzotriazole (TBB) was dissolved
in DMSO and stored at 4◦C. Stocks were diluted in
serum-free medium to working concentration at the
moment of use.
Cell cultures
The human neuroblastoma SH-SY5Y cell line from
European Collection of Cell Cultures (ECACC No.
94030304) was used for these experiments. SH-SY5Y
cells were cultured in medium with equal amount of
Eagle’s minimum essential medium and Nutrient Mix-
ture Ham’s F-12, supplemented with 10% FCS, 2 mM
glutamine, 100 U/ml penicillin, 100 µM streptomycin,
1% non-essential aminoacids at 37◦C in 5% CO2. Cells
were plated at a density of 1× 105 cells/cm2, and treat-
ments were performed after 24 h from seeding. Over-
expressing PKCε cells were obtained by transfection
of the plasmid encoding HA-tagged PKCε-[pcDNA3-
HA- PKCε] (a gift from Dr. Jae-Won Soh, Inha Univer-
sity Korea) [19]. SH-SY5Y cells were transfected with
400 ng of plasmid with Lipofectamine 2000, according
to the manufacturer’s instructions and positive clones
were selected with 400µg/ml G418 (Geneticin). PKCε
overexpression was detected in western blots with ei-
ther anti-HA antibody or anti-PKCε antibody.
Experimental treatments
Confluent monolayers of cells were washed twice
with PBS and treated at 37◦C in serum free medium
in the presence of vehicle alone or in the presence of
the compound of interest. Before treatment, cells were
incubated for 20 min with or without inhibitors; at the
end of treatment, the conditioned medium was collect-
ed for the analysis of sAβPPα release by western blot.
When the inhibitor peptide of PKCε translocation was
used, the cells were pretreated for 2 h with the inhibitor
peptide in presence of PULSinTM in serum free medi-
um and following rinsing twice with PBS and subject
to treatment.
Immunodetection of sAβPPα, PKCε, and tubulin
Conditioned medium was collected after treatment
and centrifuged at 13.000×g for 5 min to remove
detached cells and debris. Proteins in the medi-
um were quantitatively precipitated by the deoxy-
cholate/trichloroaceticacid procedure as previously de-
scribed [12]. Cell monolayers were washed twice
with ice cold PBS and lysed on the tissue culture dish
by addition of ice-cold lysis buffer (20 mM Tris/HCl
pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.2 mM 4-
(2-aminoethyl)benzenesulfonylfluoride hydrochloride
(AEBSF), 20 µg/ml leupeptin, 25 µg/ml aprotinin, 0.5
µg/ml pepstatin A and 0.5% Triton X-100). An aliquot
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of the cell lysate was used for protein analysis with
the Pierce Bicinchoninic Acid kit, for protein quantifi-
cation. Normalization of protein loading on each blot
was obtained by loading a volume of sample of con-
ditioned medium standardized to total cell lysate pro-
tein concentration. Proteins were subjected to SDS-
PAGE (10%) and then transferred onto PVDF mem-
brane 0.45 µm (Immobilon, Millipore Corp, Bedford,
MA, USA). The membrane was blocked for 1 h with
5% non-fat dry milk in Tris-buffered saline containing
1% Tween 20 (TBST). Membranes were immunoblot-
ted with the antibody 6E10 (1:1000 dilution in 5%
non fat dry milk, from Chemicon-Prodotti Gianni, Mi-
lano, Italy). The detection was carried out by incuba-
tion with horseradish peroxidase conjugated goat anti-
mouse IgG (1:10000 dilution in 5% non fat dry milk,
from Pierce, Rockford, IL, USA) for 1 h. The blots
were then washed extensively and sAβPPα visualized
using enhanced chemiluminescent methods (Pierce,
Rockford, IL, USA). For the detection of PKCε and
tubulin, proteins were measured as described earlier,
diluted in sample buffer (62.5 mM Tris/HCl pH 6.8, 2%
SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% Bro-
mophenol blue) and subjected to Western blot analysis
with the method indicated previously using the mouse
anti-human PKCε monoclonal antibody (1:10000 di-
lution in 5% non fat dry milk, from BD biosciences,
Erembodegem, Belgium) or the mouse anti α-tubulin,
clone DM1A, monoclonal antibody (at 1:5000 dilution
in 5% non fat dry milk, from Sigma Chemical Co., St.
Louis, MO,USA).
Co-immunoprecipitation
The cells were washed twice with PBS, and treated
with 100 µM CCh in serum free medium, or serum free
medium alone, for 10 and 20 min at 37◦C. Cells were
washed twice with cold PBS and lysed in immunopre-
cipitation buffer (10 mM Tris-HCl (pH 7.6), 138 mM
NaCl, 0.5% Nonidet P40, 0.2 mM AEBSF, 20 µg/ml
leupeptin, 25 µg/ml aprotinin, 0.5 µg/ml pepstatin A,
1 mM NaF). Lysed cells were sonicated twice at 40 Hz
for 10 s, and centrifuged at 12.000 × g at 4◦C for 10
min. The detergent-soluble material (supernatant) was
precleared by incubation with 20 µl of protein AG Plus
agarose (Santa Cruz Biotechnology) for 1 h at 4◦C. The
samples were centrifuged at 3.000 × g at 4◦C for 2
min, and protein quantity was determined using BCA
reagent (Pierce). Immunoprecipitation was performed
with 1 µg of mouse anti-human CK2α monoclonal an-
tibody (Chemicon, Prodotti Gianni, Milano, Italy), to-
gether with approximately 0.5–1 mg of protein diluted
in the immunoprecipitation buffer to a total volume of
500 µl. After overnight incubation at 4◦C, immuno-
complexes were collected by using protein AG Plus
agarose, incubated at 4◦C for 1 h and subsequently
washed three times with immunoprecipitation buffer.
Immunoprecipitated CK2 was recovered by resuspend-
ing the pellets in sample buffer. PKCε was detected us-
ing the mouse anti-human PKCε monoclonal antibody
at a 1:1000 dilution (BD bioscences, Erembodegem,
Belgium).
Immunocytochemical analysis of PKC and CK2
co-localization
SH-SY5Y neuroblastoma cells were seeded on glass
coverslips at a density of 1 × 105 viable cells per well
in a 24-well plate. Cells on coverslips were treated with
carbachol 100 µM in serum free medium for 20 min,
whereas control cells were incubated with medium
alone for 20 min; when indicated TBB was added 20
min prior to the treatment. After treatment, cells were
fixed in ethanol 70% at −20◦C, washed with PBS and
permeabilized for 15 min at room temperature with
0.01% Triton X-100 in PBS. Nonspecific bindings with
PKCε and CK2 were blocked by incubation for 30 min
with PBS containing 1% BSA. Cells were incubated
for 1 h with the rabbit antibody specific for PKCε (San-
ta Cruz Biotechnology Inc., CA, USA) diluted 1:50 in
PBS/1% BSA solution. After rinsing in PBS, a FITC
conjugated rabbit anti-IgG antibody (Invitrogen, CA,
USA) was diluted at 1:500 in PBS/1% BSA to detect
PKCε. Cells were then subjected to a further incuba-
tion for 1 h with a monoclonal antibody specific for
CK2 (Millipore, MA, USA) diluted 1:20 in PBS/1%
BSA solution. To detect CK2 cells were incubated for
1 h at room temperature with an anti-mouse IgG an-
tibody conjugated with ALEXA 633 (Invitrogen, CA,
USA) diluted 1:50 in PBS/1% BSA. After the fluo-
rescent labeling procedures, cells were finally counter-
stained for DNA for 5 min with a 0.1 µg/ml HOECST
33342 solution in PBS, and mounted upside down on
glass slides, in a drop of Mowiol (Calbiochem). Im-
ages were obtained with a confocal microscope Leica
DM IRBE with Leica TCS SP software.
Immunodetection of ADAM10 and TACE/ADAM17
Following 2 h of 100 µM CCh treatment in the pres-
ence or absence of 16 µM TBB, cell monolayers were
washed twice with ice cold PBS and lysed on the tissue
Galley Proof 18/05/2010; 16:59 File: jad090232.tex; BOKCTP/ljl p. 4
4 S.C. Lenzken et al. / Recruitment of Casein Kinase 2 is Involved in AβPP Processing Following Cholinergic Stimulation
culture dish by addition of ice-cold lysis buffer 20 mM
Tris/HCl pH 7.4, 0.32 M sucrose, 2 mM EDTA, 0.5 mM
EGTA, 50 mM β-mercaptoethanol, 0.2 mM AEBSF,
20 µg/ml leupeptin, 25 µg/ml aprotinin and 0.5 µg/ml
pepstatin A. Cell lysis was achieved using a Dounce
homogenizer (15–20 strokes were performed for each
sample). Cell lysates were centrifuged at 3,000 × g,
for 5 min at 4◦C, and the surnatants were separated
from the pellets (nuclei), and were further pelleted by
centrifugation for 60 min at 4◦C and 100,000× g. The
resulting pellet (referred to here as the particulate frac-
tion) was resuspended in lysis buffer 20 mM Tris/HCl
pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.2 mM AEB-
SF, 20 µg/ml leupeptin, 25 µg/ml aprotinin, 0.5 µg/ml
pepstatin A, and 0.5% Triton X-100 and an aliquot
was used for protein analysis with the Pierce Bicin-
cronic Acid kit, for protein quantification. Subsequent-
ly it was diluted in sample buffer (62.5 mM Tris/HCl
pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothre-
itol, 0.1% Bromophenol blue) and subjected to West-
ern blot analysis with the method indicated previous-
ly, using the mouse anti-ADAM10 monoclonal anti-
body (1:1000) from Abcam Inc.,Cambridge, MA, USA
or the goat anti-TACE/ADAM17 polyclonal antibody
(1:200), able to detect the C-terminal region of both
the precursor and mature TACE/ADAM17, from Santa
Cruz Biotechnology Inc., Santa Cruz, California, USA;
in both cases tubulin was also performed as a normal
control of proteins.
Densitometry and statistics
Analysis of Western blot images was performed by
calculating the relative intensity of the immunoreac-
tive bands after acquisition of the blot image through
a Nikon CCD video camera module and analysis by
means of the Image 1.47 program (Wayne Rasband,
NIH, Research Service Branch, NIMH, Bethesda, MD,
USA). The relative densities of the bands were ex-
pressed as arbitrary units and normalized to data ob-
tained from control sample run under the same condi-
tions. Controls were processed in parallel with stim-
ulated samples and always included in the same blot.
Preliminary experiments with serial dilutions of se-
creted protein allowed determination of optimal linear
range for chemiluminescence reaction. Results are re-
ported as means of three to four independent experi-
ments ± S.E.M. Statistical analysis was made by one-
way analysis of variance followed, when significant, by
the multiple comparison Bonferroni test; p < 0.05 was
considered significant.
RESULTS AND DISCUSSION
PKCε and the processing of AβPP
We produced a stable clone of SH-SY5Y neurob-
lastoma cells overexpressing PKCε. The clone (W3)
expresses higher levels of PKCε determined by west-
ern blot (Fig. 1A) and real time PCR (not shown).
The overexpressing cells were subjected to a treatment
with 100 µM of CCh in serum free medium for 2 h
and sAβPPα release was detected by western blot in
the conditioned medium. PKCε overexpressing cells,
as expected, produce a 2-fold increase in sAβPPα re-
lease compared to stimulated wild type cells (Fig. 1B).
These data are all in agreement and sustain our pre-
vious findings obtained in PKCε antisense downreg-
ulated cells [13], indicating that the main PKC iso-
form involved in the downstream events following car-
bachol stimulation is PKCε. Other authors also sug-
gested that PKCε participates in AβPP α-secretase
processing [20–22], and the fact that some PKC iso-
forms, namely PKCα, are involved mostly in consti-
tutive AβPP processing [23], indicate that the multi-
ple isoforms of PKC may be selectively involved in
different aspects of AβPP processing.
We further explored the involvement of PKCε using
a specific inhibitor, namely an inhibitor peptide mim-
icking the V1 region of PKCε, which interacts with the
Receptor for Activated C Kinase 2 (RACK2) [24,25],
in order to block the translocation of PKCε following
cholinergic stimulation. The peptide is not cell perme-
able [25], therefore the cells were pretreated for 2 h
with 5µM of inhibitor peptide using PULSin as deliver-
ing agent; following incubation, the cells were washed
with phosphate buffer and subjected to the treatment,
adding medium without serum or with 100 µM CCh
in serum free medium for 2 h. The effect of the addi-
tion of PKCε inhibitor peptide was a decrease of about
40% in sAβPPα release compared to untreated cells
(Fig. 1C) suggesting that PKCε translocation is neces-
sary for sAβPPα release. Since we used a membrane
permeating agent, the proper controls were included in
our protocol, however, no significant effect on sAβPPα
release was detected (data not shown). Overall these
data reinforce and confirm the involvement of PKCε in
carbachol stimulated AβPP processing [13]. In addi-
tion since the sequence of the inhibitor peptide is iden-
tical to the V1 region of PKCε, which is the domain of
interaction with RACK2 [24,25], the data suggest that
the anchoring protein is involved in PKCε translocation
following cholinergic stimulation. The observation that
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Fig. 1. A) Stably transfected SH-SY5Y cells show PKCε expression level about 1.6 fold higher than corresponding wild type cells. The clone
characterization was achieved by western blotting (quantitation shown in figure) and RT-PCR (not shown) evaluating the presence of both the
endogenous and esogenous form of PKCε. B) The overexpression of PKCε in the SH-SY5Y cells induces an increase in sAβPPα release about
2-fold higher than the corresponding wild type cells, in cholinergic stimulus condition upon treatment with 100 µM CCh for 2 h. C) Blocking
the translocation of PKCε with the inhibitor peptide (IP) reduces sAβPPα release after carbachol treatment. Cells have been treated with 100
µM CCh for 2 h in presence or absence of 5 µM IP (added 2 h before). ∗p < 0.05; ***p < 0.001 (Bonferroni Multiple Comparison Test).
the decrease in sAβPPα release was greatly reduced
by the peptide inhibitor but did not fully return to basal
secretion suggests that other additional mechanisms of
signal transduction may be involved.
CK2 participation in AβPP processing
As suggested by some authors [16–18],we addressed
the issue of a close relationship between the activity of
CK2 and PKCε. First of all we performed a set of exper-
iments using TBB (4,5,6,7-tetrabromobenzotriazole), a
specific inhibitor of CK2 which has been recommended
in cell-based assays [26] and observed that treatment
of SH-SY5Y cells with 16 µM TBB prior to treatment
with 100 µM CCh, reduces stimulated sAβPPα release
by 60% (Fig. 2). Interestingly, treatment with TBB also
induced an inhibition in the basal release of sAβPPα
(Fig. 2). Various TBB concentrations were assayed,
leading to the choice of the 16µM concentration, show-
ing consistent effect on sAβPPα release without signif-
icant effects on cell viability (MTT assays–not shown).
These initial results suggested an involvement of
CK2 in the pathway leading to α-secretase activation
following PKCε stimulation by cholinergic receptor
agonists.
To test the hypothesis of a direct interaction between
CK2 and PKCε, we set up an experiment in which,
following a treatment with 100 µM CCh for 10 and
20 min, cell lysates were subjected to immunoprecipi-
tation with anti-CK2 antibody. Using an immunopre-
cipitating antibody mouse anti-human alpha CK2 sub-
unit, followed by western blot for PKCε, revealed that
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Fig. 2. Inhibition of CK2 with TBB reduces the cholinergic stimulated release of sAβPPα. SH-SY5Y cells release sAβPPα as a doublet
corresponding to the AβPP isoforms expressed by the cells [12]. Cells have been pretreated with 16 µM TBB (see methods for details) for 30 min
and then treated with 100 µM CCh for 2 h. The effect of TBB is an almost complete inhibition of stimulated sAβPPα release, returning levels
of secretion almost to control levels. We have observed also a reduction of basal sAβPPα secretion which however does not reach statistical
significance. **p < 0.01; ***p < 0.001 (Bonferroni Multiple Comparison Test).
the two proteins are co-immunoprecipitated with a sig-
nificant PKCε band present already at 10 min and in-
creasing further after 20 min of CCh treatment (Fig. 3).
The data is suggestive of a direct interaction between
CK2 and PKCε that takes place immediately after the
application of CCh. The interaction between PKCε
and CK2 was also confirmed by immunocytochemical
experiments. As shown in Fig. 4, in basal conditions
(Ctrl) CK2 and PKCε are diffusely distributed at a cel-
lular level, whereas after treatment with 100 µM CCh
for 20 min, the two proteins are both localized near the
nucleus. This is further supports several reports that
suggest a clear functional relationship between PKCε
and CK2; for example, Sanghera and coworkers found
that PKCs from a brain homogenate were able to in-
crease the CK2 activity in vitro [16], whilst Boehring
and colleagues recently reported a similar increase on
CK2 activity after phorbol ester stimulation in hip-
pocampal neurons [18].
We wanted to investigate whether the activity of CK2
related to AβPP processing was located upstream or
downstream of PKC in our cellular model. Silva-Neto
Fig. 3. Co-immunoprecipitation analysis. In order to establish if
the two kinases directly interact, a co-immunoprecipitation assay has
been performed using as immunoprecipitating antibody mouse anti
CK2α, then mouse anti PKCε for western blot.
and coworkers suggested that CK2 activity could be lo-
cated downstream of PKC [17]. Previously, our group
showed that after a cholinergic stimulus, PKCε translo-
cates from the cytosol to Golgi-like structure [13]. We
treated cells with 100µM CCh for 20 min in presence or
absence of 16 µM TBB. After treatment, the cells were
fixed and immunolocalization of PKCεwas performed,
in order to observe the re-localization of this kinase
after treatment with CCh. Accordingly with previous
results, in unstimulated conditions PKCεwas distribut-
Galley Proof 18/05/2010; 16:59 File: jad090232.tex; BOKCTP/ljl p. 7
S.C. Lenzken et al. / Recruitment of Casein Kinase 2 is Involved in AβPP Processing Following Cholinergic Stimulation 7
Fig. 4. Immunolocalization of PKCε and CK2. In basal conditions PKCε, marked in green by FITC conjugated polyclonal antibody, and CK2,
marked in red by ALEXA 633 conjugated monoclonal antibody, are localized diffusely at a cellular level (panel CTRL). After 100 µM CCh
treatment for 20 min, PKCε and CK2 colocalize in Golgi-like structures. Pretreatment with 16 µM TBB for 20 min followed by 100 µM CCh
specifically inhibited CK2 translocation, without affecting PCKε subcellular localization in Golgi-like structure (panel TBB+CCh). Treatment
with only 16 µM TBB for 20 min does not alter the diffuse distribution of both PKCε and CK2 similar to basal condition (panel TBB). Confocal
image, magnification: 63x. (Colours are visible in the electronic version of the article at www.iospress.nl.)
A
B
Fig. 5. ADAM10 and ADAM17 profiles after cholinergic stimu-
lation. Western blots have been performed to detect and evaluate
the pattern of expression of the two principal putative α-secretase,
ADAM10, and ADAM17 (TACE). A) The western blot with anti
ADAM10 antibodies does not reveal changes in the pattern of the
mature and immature form of the protease during CCh challenge both
in the presence or absence of TBB. B) Western blots of ADAM17
show that the addition of CCh induces a significant modification of
the pattern of proteins which is abolished by the treatment with TBB.
ed rather uniformly in the cytosol (Ctrl); whereas, fol-
lowing cholinergic stimulation, the kinase translocated
to perinuclear Golgi-like structures. Pretreatment with
the specific inhibitor of CK2, TBB, did not affect PKCε
activation and translocation, thus suggesting that CK2
could be involved downstream of PKCε (Fig. 4) in the
CCh stimulated AβPP processing pathway.
ADAM10 and ADAM17 profiles after cholinergic
stimulation
The proteases ADAM10 and ADAM 17 (TACE) are
the most important and best characterized activities
known as α-secretases [3–5]. While TACE/ADAM17
seems to be involved only in the regulated release of
sAβPPα [3], ADAM10 appears to be affecting both
the regulated and constitutive processing of AβPP [4,
5]. We investigated whether the pattern of maturation
and distribution of ADAM 10 and ADAM 17 was af-
fected during CCh challenge. Consistent with previ-
ous reports [27], we did not observe modification of
the protein pattern of ADAM 10 after CCh treatment
(Fig. 5A). We have, however, observed a modification
of the protein profile of ADAM17 after challenge with
CCh (Fig. 5B). Similarly to the pattern described by
Alfa Cisse` et al. [28], CCh decreased the appearance
of a band that may be ascribed to an active state of
ADAM17 as suggested to occur following cholinergic
stimulation. Pretreatment with TBB, the specific in-
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Fig. 6. Schematic pathway of CK2 involvement in AβPP processing downstream of cholinergic stimulation. Carbachol stimulates M1 and M3
muscarinic receptors (mAChR) and the nicotinic receptor (nAChR) activating PKCε which in turn interacts with CK2. This signaling cascade
results in sAβPPα release after the AβPP proteolityc cleavage by ADAM10 and especially by ADAM17 as a consequence of their activation by
CK2.
hibitor of CK2, abolished the capability of CCh to mod-
ulate the profile of ADAM17 (Fig. 5B). It is possible to
speculate that the pattern expressed by ADAM17 is de-
rived from the involvement of pro-protein convertates
such as furin, which has been suggested to be one of the
proteolytic activator of ADAMs [29]. Moreover other
authors identified in the structure of furin a consensus
sequence for CK2 phosphorylation [30], an event that
can occur in vivo [31]. We cannot rule out the possibil-
ity that the evidence described for the involvement of
CK2 in the regulated processing of AβPP depends on
one or more of these mechanisms.
Overall, our data suggest that the stimulation of
cholinergic receptors by carbachol leads to regulated
AβPP processing and release of sAβPPα, through the
activation of a signaling cascade that involves specifi-
cally PKCε which in turn interacts with CK2 and leads
to activation of ADAM17 (as the main α secretase in-
volved) (Fig. 6).
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